BioStem Technologies will participate in the Symposium on Advanced Wound Care Spring meeting in Charlotte, North Carolina, from April 8-12, 2026, where the company plans to highlight its expanded product portfolio and clinical research. The symposium represents one of the premier gatherings for wound care professionals, clinicians, and researchers, making BioStem's presentation significant for the medical community and patients dealing with chronic wounds.
The company's participation centers on its recently introduced Neox product line, which expands BioStem's capabilities across multiple tissue formats. According to Chairman and CEO Jason Matuszewski, this addition provides physicians with differentiated options depending on clinical need, handling preferences, and site-of-care requirements. The expanded portfolio now offers what the company describes as the most comprehensive suite of placental and umbilical cord tissue solutions, backed by both randomized clinical trials and real-world evidence.
Beyond exhibit booth presentations scheduled for Thursday through Saturday, BioStem is hosting a lunch symposium titled "A New Season in Wound Care: An Expanded Portfolio Grounded in Evidence" on Thursday, April 9th, from 12:15 p.m. to 1:45 p.m. in Room 207C. The session will feature presentations by Dr. Wendy Weston, Dr. William Marston, and Dr. Herbert Slade, covering several key topics including the science behind BioStem's birth tissue products, recently published results of a randomized controlled trial on diabetic foot ulcers, and practical guidance on incorporating these therapies into clinical practice.
The company will also present a new scientific poster (LR-020) in Exhibit Hall 1C, demonstrating its continued investment in clinical research and medical education. This research initiative aims to expand access to advanced healing technologies across a wide range of care settings. BioStem's quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks, established in compliance with current Good Tissue Practices and current Good Manufacturing Processes.
The importance of BioStem's presentation at SAWC lies in the growing need for effective wound care solutions, particularly for chronic conditions like diabetic foot ulcers that affect millions globally. The company's focus on evidence-based therapies backed by clinical research addresses a critical gap in wound management, where many current treatments have limited efficacy. By expanding its product portfolio and supporting it with scientific validation, BioStem aims to provide clinicians with more tools to improve patient outcomes in various care settings.
For those interested in following company developments, additional information is available through the company's website at https://www.biostemtechnologies.com and news updates relating to the company are available at https://tinyurl.com/bsemnewsroom. BioStem's portfolio includes its Neox, Clarix, VENDAJE and American Amnion product lines, all processed using proprietary technologies designed to optimize tissue preservation for clinical use.
